Daniel Molin – Clinical and translational research in lymphoma, especially Hodgkin lymphoma

Exploratory study linking plasma proteomics to cardiotoxicity in Hodgkin lymphoma.

Mattson Ulfstedt, Johan; Risebro, Ragnhild; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-oncology, 2026

• DOI for Exploratory study linking plasma proteomics to cardiotoxicity in Hodgkin lymphoma.
• Download full text (pdf) of Exploratory study linking plasma proteomics to cardiotoxicity in Hodgkin lymphoma.

Personalized organ dose assessment from CT imaging during proton therapy for classical Hodgkin lymphoma patients

Gkavonatsiou, Angeliki; Romero-Expósito, Maite; Andersson, Karin M.; Azizi, Mona et al.

Part of Physica medica (Testo stampato), 2026

• DOI for Personalized organ dose assessment from CT imaging during proton therapy for classical Hodgkin lymphoma patients
• Download full text (pdf) of Personalized organ dose assessment from CT imaging during proton therapy for classical Hodgkin lymphoma patients

A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma

Lia, Kjersti; Jørgensen, Rasmus Rask Kragh; Wikman, Per; Wold, Bente L. et al.

Part of Haematologica, p. 2356-2366, 2025

• DOI for A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma
• Download full text (pdf) of A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

Viviani, Simonetta; Pavoni, Chiara; Barrington, Sally F.; Guerra, Luca et al.

Part of Blood Cancer Journal, 2025

• DOI for Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
• Download full text (pdf) of Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients

Broeckelmann, Paul J.; Boell, Boris; Molin, Daniel; Schneider, Gundolf et al.

Part of HemaSphere, 2025

• DOI for Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial

Fossa, Alexander; Molin, Daniel; Broeckelmann, Paul J.; Schneider, Gundolf et al.

Part of HemaSphere, 2025

• DOI for Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial
• Download full text (pdf) of Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial

Ferdinandus, Justin; Schneider, Gundolf; Moccia, Alden; Greil, Richard et al.

Part of The Lancet Oncology, p. 1081-1090, 2025

• DOI for Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
• Download full text (pdf) of Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial

Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy

Molin, Daniel

Part of Acta Oncologica, p. 1540-1543, 2025

• DOI for Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy
• Download full text (pdf) of Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy

Individualized evaluation of the total dose received by radiotherapy patients: Integrating in-field, out-of-field, and imaging doses

Romero-Expósito, Maite; Sánchez-Nieto, Beatriz; Riveira-Martin, Mercedes; Azizi, Mona et al.

Part of Physica medica (Testo stampato), 2025

• DOI for Individualized evaluation of the total dose received by radiotherapy patients: Integrating in-field, out-of-field, and imaging doses
• Download full text (pdf) of Individualized evaluation of the total dose received by radiotherapy patients: Integrating in-field, out-of-field, and imaging doses

Response to Comment on: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma"

Lia, Kjersti; Rask Kragh Jorgensen, Rasmus; Wikman, Per; Wold, Bente L. et al.

Part of Haematologica, p. 2866-2867, 2025

• DOI for Response to Comment on: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma"
• Download full text (pdf) of Response to Comment on: "A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma"

Aging Kairos: treating older Hodgkin patients

Molin, Daniel

Part of Blood, p. 943-945, 2024

• DOI for Aging Kairos: treating older Hodgkin patients

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Borchmann, Peter; Ferdinandus, Justin; Schneider, Gundolf; Moccia, Alden et al.

Part of The Lancet, p. 341-352, 2024

• DOI for Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
• Download full text (pdf) of Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: A Swedish matched cohort study

Baech, Joachim; El-Galaly, Tarec Christoffer; Entrop, Joshua P.; Glimelius, Ingrid et al.

Part of eJHaem, p. 1190-1200, 2024

• DOI for Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: A Swedish matched cohort study
• Download full text (pdf) of Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: A Swedish matched cohort study

Diagnostik och behandling av klassiskt Hodgkins lymfom

Molin, Daniel

Part of Läkartidningen, 2024

Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers

Forsgren, Elin; Ekberg, Sara; Smedby, Karin E.; Nylund, Patrick et al.

Part of British Journal of Haematology, p. 1794-1803, 2024

• DOI for Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers
• Download full text (pdf) of Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers

Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study

Ekberg, Sara; Molin, Daniel; Pahnke, Simon; Bergstroem, Fanny et al.

Part of Acta Oncologica, p. 164-168, 2024

• DOI for Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study
• Download full text (pdf) of Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study

Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors

Tarai, Sambit; Lundström, Elin; Sjöholm, Therese; Jönsson, Hanna et al.

Part of Heliyon, 2024

• DOI for Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors
• Download full text (pdf) of Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors

Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial

Luminari, Stefano; Fossa, Alexander; Trotman, Judith; Molin, Daniel et al.

Part of Journal of Clinical Oncology, p. 13-18, 2024

• DOI for Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
• Download full text (pdf) of Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial

The National Swedish Lymphoma Register - a systematic validation of data quality

Smedby, Karin E.; Eloranta, Sandra; Wasterlid, Tove; Falini, Victor et al.

Part of Acta Oncologica, p. 563-572, 2024

• DOI for The National Swedish Lymphoma Register - a systematic validation of data quality
• Download full text (pdf) of The National Swedish Lymphoma Register - a systematic validation of data quality

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Armand, Philippe; Zinzani, Pier Luigi; Lee, Hun Ju; Johnson, Nathalie A. et al.

Part of Blood, p. 878-886, 2023

• DOI for Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

NLPHL: a hummingbird in an owl's nest

Molin, Daniel

Part of Blood, p. 499-500, 2023

• DOI for NLPHL: a hummingbird in an owl's nest

Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study

Entrop, Joshua P.; Weibull, Caroline E.; Smedby, Karin E.; Jakobsen, Lasse H. et al.

Part of International Journal of Cancer, p. 723-731, 2023

• DOI for Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
• Download full text (pdf) of Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma

Nikkarinen, Anna; Lokhande, Lavanya; Amini, Rose-Marie; Jerkeman, Mats et al.

Part of Blood Advances, p. 5304-5313, 2023

• DOI for Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma

An image registration method for voxel-wise analysis of whole-body oncological PET-CT

Jönsson, Hanna; Ekström, Simon; Strand, Robin; Pedersen, Mette A et al.

Part of Scientific Reports, 2022

• DOI for An image registration method for voxel-wise analysis of whole-body oncological PET-CT
• Download full text (pdf) of An image registration method for voxel-wise analysis of whole-body oncological PET-CT

Checkpoint CD47 expression in classical Hodgkin lymphoma

Gholiha, Alex Reza; Hollander, Peter; Löf, Liza; Glimelius, Ingrid et al.

Part of British Journal of Haematology, p. 580-589, 2022

• DOI for Checkpoint CD47 expression in classical Hodgkin lymphoma
• Download full text (pdf) of Checkpoint CD47 expression in classical Hodgkin lymphoma

Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity

Hellbacher, Erik; Sundström, Christer; Molin, Daniel; Baecklund, Eva et al.

Part of Cancers, 2022

• DOI for Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity
• Download full text (pdf) of Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue

Gholiha, Alex R.; Hollander, Peter; Löf, Liza; Larsson, Anders et al.

Part of Cancers, 2022

• DOI for Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
• Download full text (pdf) of Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Lagerlöf, Ingemar; Fohlin, Helena; Enblad, Gunilla; Glimelius, Bengt et al.

Part of Journal of Clinical Oncology, p. 1487-1496, 2022

• DOI for Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
• Download full text (pdf) of Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Sabaa, Amal Abu; Shen, Qiujin; Lennmyr, Emma; Enblad, Anna Pia et al.

Part of New Biotechnology, p. 21-29, 2022

• DOI for Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
• Download full text (pdf) of Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?

Andersson, Anne; Enblad, Gunilla; Erlanson, Martin; Johansson, Ann-Sofie et al.

Part of Upsala Journal of Medical Sciences, 2021

• DOI for High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?
• Download full text (pdf) of High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-Oncology, 2021

• DOI for Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders

Kinch, Amelie; Baecklund, Eva; Molin, Daniel; Pauksen, Karlis et al.

Part of Acta Oncologica, p. 771-778, 2021

• DOI for Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders
• Download full text (pdf) of Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Vajavaara, Heli; Ekeblad, Frida; Holte, Harald; Jorgensen, Judit et al.

Part of Haematologica, p. 2502-2506, 2021

• DOI for Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

Wahlin, Bjoern Engelbrekt; Övergaard, Ninja; Peterson, Stefan; Digkas, Evangelos et al.

Part of eJHaem, p. 400-412, 2021

• DOI for Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
• Download full text (pdf) of Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma

Gholiha, Alex R.; Hollander, Peter; Glimelius, Ingrid; Hedström, Gustaf et al.

Part of Blood Advances, p. 1671-1681, 2021

• DOI for Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

Mattsson Ulfstedt, Johan; Venge, Per; Holmgren, Sofia; Enblad, Gunilla et al.

Part of Upsala Journal of Medical Sciences, 2021

• DOI for Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma
• Download full text (pdf) of Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

CD30 expression and survival in posttransplant lymphoproliferative disorders

Kinch, Amelie; Amini, Rose-Marie; Hollander, Peter; Molin, Daniel et al.

Part of Acta Oncologica, p. 673-680, 2020

• DOI for CD30 expression and survival in posttransplant lymphoproliferative disorders
• Download full text (pdf) of CD30 expression and survival in posttransplant lymphoproliferative disorders

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Jakobsen, Lasse H.; Ellin, Fredrik; Smeland, Knut B.; Wästerlid, Tove et al.

Part of British Journal of Haematology, p. 661-671, 2020

• DOI for Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Lagerlöf, Ingemar; Holte, Harald; Glimelius, Ingrid; Björkholm, Magnus et al.

Part of British Journal of Haematology, p. 685-691, 2020

• DOI for No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Pembrolizumab in relapsed or refractory Richter syndrome

Armand, Philippe; Murawski, Niels; Molin, Daniel; Zain, Jasmine et al.

Part of British Journal of Haematology, 2020

• DOI for Pembrolizumab in relapsed or refractory Richter syndrome
• Download full text (pdf) of Pembrolizumab in relapsed or refractory Richter syndrome

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Zinzani, Pier Luigi; Chen, Robert; Armand, Philippe; Johnson, Nathalie A. et al.

Part of Leukemia and Lymphoma, p. 950-954, 2020

• DOI for Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma

Hollander, Peter; Ginman, Beatrice; Molin, Daniel; Enblad, Gunilla et al.

Part of Immunobiology, 2020

• DOI for Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma
• Download full text (pdf) of Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma

Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation

Kinch, Amelie; Sundström, Christer; Baecklund, Eva; Backlin, Carin et al.

Part of Leukemia and Lymphoma, p. 376-384, 2019

• DOI for Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation
• Download full text (pdf) of Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation

Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy

Pedersen, Mette A.; Gormsen, Lars C.; Kamper, Peter; Wassberg, Cecilia et al.

Part of British Journal of Haematology, p. 431-439, 2019

• DOI for Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms

Gholiha, Alex R.; Hollander, Peter; Hedström, Gustaf; Sundström, Christer et al.

Part of British Journal of Haematology, p. 192-201, 2019

• DOI for High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms

Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival

Lundberg, Josefine; Berglund, David; Molin, Daniel; Kinch, Amelie

Part of Upsala Journal of Medical Sciences, p. 105-110, 2019

• DOI for Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival
• Download full text (pdf) of Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Chen, Robert; Zinzani, Pier Luigi; Lee, Hun Ju; Armand, Philippe et al.

Part of Blood, p. 1144-1153, 2019

• DOI for Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Hollander, Peter; Rostgaard, Klaus; Ekström-Smedby, Karin; Molin, Daniel et al.

Part of European Journal of Haematology, p. 88-97, 2018

• DOI for An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
• Download full text (pdf) of An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Mörth, Charlott; Valachis, Antonis; Sabaa, Amal Abu; Molin, Daniel et al.

Part of Annals of Hematology, p. 2129-2135, 2018

• DOI for Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
• Download full text (pdf) of Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Hollander, Peter; Amini, Rose-Marie; Ginman, Beatrice; Molin, Daniel et al.

Part of PLOS ONE, 2018

• DOI for Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
• Download full text (pdf) of Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome.

Englund, Annika; Glimelius, Ingrid; Rostgaard, Klaus; Smedby, Karin E et al.

Part of Acta Oncologica, p. 276-282, 2018

• DOI for Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome.
• Download full text (pdf) of Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome.

High proportions of PD-1⁺ and PD-L1⁺ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Hollander, Peter; Kamper, Peter; Smedby, Karin Ekstrom; Enblad, Gunilla et al.

Part of Blood Advances, p. 1427-1439, 2017

• DOI for High proportions of PD-1⁺ and PD-L1⁺ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry

Molin, Daniel; Linderoth, Johan; Wahlin, Björn E.

Part of British Journal of Haematology, p. 449-456, 2017

• DOI for Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Chen, Robert; Zinzani, Pier Luigi; Fanale, Michelle A.; Armand, Philippe et al.

Part of Journal of Clinical Oncology, p. 2125-2132, 2017

• DOI for Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

High Expression Of Programmed Cell Death Receptor 1 In The Tumor Microenvironment Is Associated With Inferior Event Free Survival In Classical Hodgkin Lymphoma

Hollander, Peter; Kamper, P.; Smedby, K. E.; Enblad, Gunilla et al.

Part of Haematologica, p. 1-2, 2016

Hodgkin Lymphoma In Children, Adolescents And Young Adults-A Comparative Study Of Clinical Presentation And Treatment Outcome

Englund, Annika; Glimelius, Bengt; Rostgaard, K.; Eloranta, S. et al.

Part of Haematologica, p. 36-36, 2016

Hodgkin Lymphoma In Sweden Since 2000: Better Survival Only In Elderly Women - A Swedish Lymphoma Registry Study

Wahlin, B. E.; Overgaard, N.; Peterson, S.; Digkas, E. et al.

Part of Haematologica, p. 22-22, 2016

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study

Jakobsen, Lasse H; Hutchings, Martin; de Nully Brown, Peter; Linderoth, Johan et al.

Part of British Journal of Haematology, p. 236-244, 2016

• DOI for No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Barrington, Sally F; Kirkwood, Amy A; Franceschetto, Antonella; Fulham, Michael J et al.

Part of Blood, p. 1531-1538, 2016

• DOI for PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment

Hollander, Peter; Rostgaard, K.; Smedby, K. E.; Molin, Daniel et al.

Part of Haematologica, p. 3-3, 2016

The Importance Of Bone Marrow 18F-Fdg Uptake And Focal Skeletal Lesions On Survival In Patients With Newly Diagnosed Hodgkin Lymphoma

Pedersen, M. A.; Gormsen, L. C.; Kamper, P.; d'Amore, A. et al.

Part of Haematologica, p. 42-42, 2016

The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children

Englund, Annika; Molin, Daniel; Enblad, Gunilla; Karlén, Jonas et al.

Part of European Journal of Haematology, p. 430-438, 2016

• DOI for The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children
• Download full text (pdf) of The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children

Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders: Clinical Features and Survival Outcomes

Berglund, David; Kinch, Amelie; Edman, Elin; Backlin, Carin et al.

Part of Transplantation, p. 1036-1042, 2015

• DOI for Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders: Clinical Features and Survival Outcomes

Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes

Mosavi, Firas; Wassberg, Cecilia; Selling, Jonas; Molin, Daniel et al.

Part of Clinical Radiology, p. 1229-1236, 2015

• DOI for Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes

A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.

Kinch, Amelie; Baecklund, Eva; Backlin, Carin; Ekman, Tor et al.

Part of Acta Oncologica, p. 669-679, 2014

• DOI for A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Gormsen, Lars C.; Wassberg, Cecilia; Molin, Daniel; Kamper, Peter et al.

Part of Blood, 2014

Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma: pathological development and restitution

Hallén, Karin; Sangfelt, Per; Nilsson, Thomas; Nordgren, Hans et al.

Part of Acta Oncologica, p. 1271-1275, 2014

• DOI for Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma: pathological development and restitution

Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma

Glimelius, Ingrid; Qvarnström, Fredrik; Simonsson, Martin; Ekwall, Anders et al.

Part of Histopathology, p. 26-32, 2012

• DOI for Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma

Long term risk of infections in Hodgkin lymphoma long-term survivors

Andersson, Anne; Enblad, Gunilla; Gustavsson, Anita; Erlanson, Martin et al.

Part of British Journal of Haematology, p. 661-663, 2011

• DOI for Long term risk of infections in Hodgkin lymphoma long-term survivors

Pediatric Organ Transplantation and Risk of Premalignant and Malignant Tumors in Sweden

Simard, J. F.; Baecklund, Eva; Kinch, Amelie; Brattström, C. et al.

Part of American Journal of Transplantation, p. 146-151, 2011

• DOI for Pediatric Organ Transplantation and Risk of Premalignant and Malignant Tumors in Sweden

Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's Lymphoma: a population-based study

Glimelius, Ingrid; Rubin, Jenny; Rostgaard, Klaus; Amini, Rose Marie et al.

Part of European Journal of Haematology, p. 208-216, 2011

• DOI for Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's Lymphoma: a population-based study

The effect of Eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines

Glimelius, Ingrid; Rubin, Jenny; Fischer, Marie; Molin, Daniel et al.

Part of Experimental Hematology, p. 850-858, 2011

• DOI for The effect of Eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines

Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients

Abdul Qadhr, Göran; Molin, Daniel; Åström, Gunnar; Suurküla, Madis et al.

Part of Acta Radiologica, p. 173-180, 2011

• DOI for Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients

A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

Enciso-Mora, Victor; Broderick, Peter; Ma, Yussanne; Jarrett, Ruth F. et al.

Part of Nature Genetics, p. 1126-1130, 2010

• DOI for A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: A report of two cases

Molin, Daniel; Hagberg, Hans; Suurküla, Madis; Åström, Gunnar

Part of Acta Oncologica, p. 526-528, 2010

• DOI for Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: A report of two cases

Framgångens baksida: Sena biverkningar av strålbehandling vid Hodgkins lymfom

Molin, Daniel

Part of Läkartidningen, p. 2731-2732, 2010

Framgångens baksida: Sena biverkningar av strålbehandling vid Hodgkins lymfom

Molin, Daniel

Part of Läkartidningen, p. 2731-2732, 2010

Mast cells in squamous cell esophageal carcinoma and clinical parameters

Tinge, Beatrice; Molin, Daniel; Bergqvist, Michael; Ekman, Simon et al.

Part of Cancer Genomics & Proteomics, p. 25-29, 2010

Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma

Biggar, Robert J.; Johansen, Julia S.; Smedby, Karin Ekström; Rostgaard, Klaus et al.

Part of Clinical Cancer Research, p. 6974-8, 2008

• DOI for Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma

Cigarette smoking and risk of Hodgkin lymphoma: a population-based case-control study

Hjalgrim, Henrik; Ekström-Smedby, Karin; Rostgaard, Klaus; Amini, Rose-Marie et al.

Part of Cancer Epidemiology, Biomarkers and Prevention, p. 1561-1566, 2007

• DOI for Cigarette smoking and risk of Hodgkin lymphoma: a population-based case-control study

Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma

Hjalgrim, Henrik; Smedby, Karin Ekström; Rostgaard, Klaus; Molin, Daniel et al.

Part of Cancer Research, p. 2382-2388, 2007

• DOI for Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma

Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma

Hedström, Gustaf; Berglund, Mattias; Molin, Daniel; Fischer, Marie et al.

Part of British Journal of Haematology, p. 68-71, 2007

• DOI for Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma

The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma

Enblad, Gunilla; Molin, Daniel; Glimelius, Ingrid; Fischer, Marie et al.

Part of Hematology/Oncology Clinics of North America, p. 805-823, 2007

• DOI for The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma

IL-9 expression contributes to the cellular composition in Hodgkin lymphoma

Glimelius, Ingrid; Edström, Annika; Amini, Rose-Marie; Fischer, Marie et al.

Part of European Journal of Haematology, p. 278-283, 2006

• DOI for IL-9 expression contributes to the cellular composition in Hodgkin lymphoma

Angiogenesis and mast cells in Hodgkin lymphoma

Glimelius, Ingrid; Edström, Annika; Fischer, Marie; Nilsson, Gunnar et al.

Part of Leukemia, p. 2360-2362, 2005

• DOI for Angiogenesis and mast cells in Hodgkin lymphoma

Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL).

Torell, Erik; Molin, Daniel; Tano, Eva; Ehrenborg, Christian et al.

Part of Scand J Infect Dis, p. 902-4, 2005

Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.

Molin, Daniel

Part of Ups J Med Sci, p. 179-228, 2004

Increased serum levels of Interleukin-9 correlates with negative prognostic factors in Hodgkin's lymphoma

Fischer, Marie; Molin, Daniel; Bijman, Marcel; Cormont, Francoise et al.

Part of Leukemia, p. 2513, 2003

Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma

Molin, Daniel; Edström, Annika; Glimelius, Ingrid; Glimelius, Bengt et al.

Part of British Journal of Haematology, p. 122-124, 2002

• DOI for Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma

Comprehensive blood plasma proteomics identifies VSIG4 and CD169 as prospective biomarkers for high-risk of early relapse in mantle cell lymphoma

Nylund, Patrick; Selvin, Tove; Nikkarinen, Anna; Ly, Ann-Marie et al.

Plasma Protein Profiling using Multiplex Extension Assay in Diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: A descriptive study

Abu Sabaa, Amal; Mörth, Charlott; Molin, Daniel; Freyhult, Eva et al.

Real-life data on morbidity and cause-specific mortality after combined modality treatment for Hodgkin lymphoma 2006-2015.

Lagerlöf, Ingemar; Wikman, Per; Enblad, Gunilla; Goldkuhl, Christina et al.

Second cancer is the leading cause of death, with no increase of cardiovascular deaths, after combined modality Hodgkin lymphoma treatment

Lagerlöf, Ingemar; Fohlin, Helena; Enblad, Gunilla; Glimelius, Bengt et al.